ACST שיעור רווח גולמי Acasti Pharma

סמלים רשמיים של חברת Acasti Pharma (ACST)

Acasti Pharma (ACST) develops drugs for rare cardiac pathologies, rendering the company insensitive to economic cycles. Specialized patents for drug delivery methods protect its niche, although limited capital creates risks. The gross profit margin as a percentage of revenue on the GURU.Markets daily chart reaches 0.00. However, the high cost of clinical trials and the probability of regulatory rejection remain the primary barriers.

Acasti Pharma Inc. (ACST): שולי רווח גולמי מ-04.07.2022 עד 28.10.2024

פילוחי מדדים פיננסיים ומדדי שוק עבור Acasti (ACST)

- שווי שוק ותחזית יעד של אנליסטים:
ניתוח בסיסי של החברה:ACST - Acasti Pharma Inc.
מוצר המיוצר על ידי Acasti Pharma Inc

FDA orphan drug status protects Acasti Pharma (ACST) from competitive pricing pressure, ensuring high added value for its medications. By analyzing the gross profit margin, an investor assesses the efficiency of direct production cost management relative to total revenue. This metric measures the remaining funds after deducting the cost of goods sold, which is critical for evaluating the fundamental stability of a biopharmaceutical asset.